Evidence map›Paper›PMID 32893062›Full record

ReviewEuropean urology2020

The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future.

Christopher J D Wallis, James W F Catto, Antonio Finelli, Adam W Glaser, John L Gore, Stacy Loeb, Todd M Morgan, Alicia K Morgans, Nicolas Mottet, Richard Neal and 8 more

Open access · greenAbstract readReview
In one paragraph

Review in European urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Burden of Parkinson's disease in Iran: disparities, trends, and the impact of social development indicators.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 12 institutions in 3 countries.

Christopher J D WallisDepartment of Urology, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: wallis.cjd@gmail.com.
James W F CattoAcademic Urology Unit, University of Sheffield, Sheffield, UK.
Antonio FinelliDivision of Urology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.
Adam W GlaserLeeds Institute of Medical Research, University of Leeds, Leeds, UK.
John L GoreDepartment of Urology, University of Washington, Seattle, WA, USA.
Stacy LoebDepartment of Urology and Population Health, NYU Langone Health and Manhattan Veterans Affairs, New York, NY, USA.
Todd M MorganDepartment of Urology, University of Michigan, Ann Arbor, MI, USA.
Alicia K MorgansDepartment of Medical Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Nicolas MottetDepartment of Urology, University Hospital Nord, St Etienne, France.
Richard NealLeeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Tim O'BrienDepartment of Urology, Guy's and St Thomas Hospitals, London, UK.
Anobel Y OdishoDepartment of Urology and Center for Digital Health Innovation, University of California San Francisco, San Francisco, CA, USA.
Thomas PowlesBarts Cancer Center, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.
Ted A SkolarusDepartment of Urology, University of Michigan, Ann Arbor, MI, USA; Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI, USA.
Angela B SmithDepartment of Urology, University of North Carolina, Chapel Hill, NC, USA.
Bernadett SzabadosBarts Cancer Center, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.
Zachary KlaassenDepartment of Surgery, Division of Urology, Augusta University-Medical College of Georgia, Augusta, GA, USA.
Daniel E SprattDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
University of Michigan · USQueen Mary University of London · GBUniversity of Leeds · GBAugusta University · USNorthwestern University · USSt Thomas' Hospital · GBUniversity of California, San Francisco · USUniversity of North Carolina at Chapel Hill · USUniversity of Sheffield · GBUniversity of Toronto · CAUniversity of Washington · USVanderbilt University Medical Center · US

Funding

De-implementation of low value castration for men with prostate cancerR37CA222885 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SAINI, SAMEER DEV, SKOLARUS, TED ALBERT · 2018 to 2023
$3.6M
Refining castration use for recurrent prostate cancerR01CA242559 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SKOLARUS, TED ALBERT, TSODIKOV, ALEXANDER · 2020 to 2023
$1.4M
NCI NIH HHS R01 CA242559NCI NIH HHS R37 CA222885
6 · The paper itself

Abstract

contextThe coronavirus disease 2019 (COVID-19) pandemic necessitated rapid changes in medical practice. Many of these changes may add value to care, creating opportunities going forward.

objectiveTo provide an evidence-informed, expert-derived review of genitourinary cancer care moving forward following the initial COVID-19 pandemic. EVIDENCE ACQUISITION: A collaborative narrative review was conducted using literature published through May 2020 (PubMed), which comprised three main topics: reduced in-person interactions arguing for increasing virtual and image-based care, optimisation of the delivery of care, and the effect of COVID-19 in health care facilities on decision-making by patients and their families. EVIDENCE SYNTHESIS: Patterns of care will evolve following the COVID-19 pandemic. Telemedicine, virtual care, and telemonitoring will increase and could offer broader access to multidisciplinary expertise without increasing costs. Comprehensive and integrative telehealth solutions will be necessary, and should consider patients' mental health and access differences due to socioeconomic status. Investigations and treatments will need to maximise efficiency and minimise health care interactions. Solutions such as one stop clinics, day case surgery, hypofractionated radiotherapy, and oral or less frequent drug dosing will be preferred. The pandemic necessitated a triage of those patients whose treatment should be expedited, delayed, or avoided, and may persist with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in circulation. Patients whose demographic characteristics are at the highest risk of complications from COVID-19 may re-evaluate the benefit of intervention for less aggressive cancers. Clinical research will need to accommodate virtual care and trial participation. Research dissemination and medical education will increasingly utilise virtual platforms, limiting in-person professional engagement; ensure data dissemination; and aim to enhance patient engagement.

conclusionsThe COVID-19 pandemic will have lasting effects on the delivery of health care. These changes offer opportunities to improve access, delivery, and the value of care for patients with genitourinary cancers but raise concerns that physicians and health administrators must consider in order to ensure equitable access to care. PATIENT SUMMARY: The coronavirus disease 2019 (COVID-19) pandemic has dramatically changed the care provided to many patients with genitourinary cancers. This has necessitated a transition to telemedicine, changes in threshold or delays in many treatments, and an opportunity to reimagine patient care to maintain safety and improve value moving forward.

Indexed as

Coronavirus InfectionsDelivery of Health CarePandemicsPneumonia, ViralPractice Patterns, Physicians'Urogenital NeoplasmsCommunicable Disease ControlCOVID-19HumansMental HealthOrganizational InnovationTelemedicineBiomedical researchHealth services accessibilityMental healthPandemicTelemedicine

Identifiers

PMID32893062
PMCPMC7471715
OpenAlexW3081748145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.